RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 4, 2025 /EINPresswire / -- How Has the Beyfortus Market Expanded in Recent Years? The Beyfortus market has experienced significant growth, driven by ...

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why AZN stock is a Buy.

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centres for Disease Control and ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

Upcoming market catalysts for the second quarter of 2025 include the US approval decisions for clesrovimab (MK-1654) for respiratory syncytial virus (RSV) prophylaxis, sebetralstat for hereditary ...

Dupixent made about €13 billion in its first full year, while Beyfortus, a novel RSV vaccination for babies, became a bestseller with €1.7 billion. SNY’s EPS grew 4.1% at CER to €7.12 ...